NCT02899052: Phase 2: Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in RRMM
Updated: Jun 15, 2022
NCT02899052: Phase 2: Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
Venetoclax + Kd
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in participants with relapsed or refractory MM and have received 1 to 3 prior lines of therapy.
Part 4 of this study is currently enrolling.
Sponsor
AbbVie
Collaborator
Genentech, Inc; Onyx Therapeutics, Inc.
Multiple Locations
International Study
ClinicalTrials.gov Identifier: NCT02899052
Official Title: A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
First Posted : September 14, 2016
Click here for details on ClinicalTrials.gov
Drug: Carfilzomib
Drug: Venetoclax
Drug: Dexamethasone
Blood Adv;2021
Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma
Treatment with VenKd was well tolerated and showed promising response rates in this RRMM patient population, with greater responses observed in patients with t(11;14). This trial is registered at www.clinicaltrials.gov
Locations
United States, Alabama
United States, Arkansas
United States, Florida
United States, Georgia
United States, Illinois
United States, Indiana
United States, Kentucky
United States, Maine
United States, Maryland
United States, Missouri
United States, North Carolina
United States, Pennsylvania
United States, Texas
United States, Utah
United States, Washington
United States, Wisconsin
Puerto Rico
Australia, New South Wales
Australia, South Australia
Australia, Tasmania
Europe
Spain
Hungary